Locally Advanced Prostate Cancer: Optimal Therapy in Older Patients

被引:2
作者
Froehner, Michael [1 ]
Wirth, Manfred P. [1 ]
机构
[1] Tech Univ Dresden, Dept Urol, Univ Hosp Carl Gustav Carus, D-01304 Dresden, Germany
关键词
ANDROGEN-DEPRIVATION THERAPY; RADICAL PROSTATECTOMY; FOLLOW-UP; BIOCHEMICAL RECURRENCE; CARDIOVASCULAR DEATH; FUNCTIONAL OUTCOMES; RADIATION-THERAPY; ONCOLOGY-GROUP; MEN; ASSOCIATION;
D O I
10.1007/s40266-013-0123-7
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
There is no standard treatment for locally advanced prostate cancer. Even the definition is still unclear. Locally advanced disease may refer to over-staged well-curable tumors as well as to advanced and probably incurable cancers. Similar uncertainties are present regarding the definition of 'old' in this context. Conservatively treated locally advanced prostate cancer is associated with poor survival outcome. With the increasing life expectancy, in the absence of curative treatment, even patients in their ninth decade of life may later suffer from symptoms of aggressive prostate cancer and are at a high risk of death from prostate cancer that might be prevented at least in part by early intervention. On the other hand, functional results after prostate cancer treatment are worse in elderly patients. In this article we discuss aspects of the management of locally advanced prostate cancer in the elderly with special focus on the recommendation of current clinical guidelines.
引用
收藏
页码:959 / 967
页数:9
相关论文
共 50 条
  • [41] Current treatment of locally advanced and metastatic prostate cancer
    Ponholzer A.
    Steinbacher F.
    Madersbacher S.
    Schramek P.
    Wiener Medizinische Wochenschrift, 2011, 161 (15-16) : 377 - 381
  • [42] Localized and Locally Advanced Prostate Cancer: Treatment Options
    Achard, Verane
    Panje, Cedric Michael
    Engeler, Daniel
    Zilli, Thomas
    Putora, Paul Martin
    ONCOLOGY, 2021, : 413 - 421
  • [43] Impact of positive surgical margin on biochemical recurrence following radical prostatectomy in locally advanced prostate cancer
    Ceylan, Cavit
    Tonyali, Senol
    Keles, Ibrahim
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2016, 32 (10) : 514 - 517
  • [44] Treatment of locally advanced prostate cancer
    Wirth, MP
    Hakenberg, OW
    Fröhner, M
    UROLOGE, 2005, 44 (11): : 1295 - 1302
  • [45] Optimal Treatment for Patients with Oligometastatic Prostate Cancer
    Cetin, Bulent
    Wabl, Chiara A.
    Gumusay, Ozge
    UROLOGIA INTERNATIONALIS, 2022, 106 (03) : 217 - 226
  • [46] Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China
    Ye, Dingwei
    Zhang, Wei
    Ma, Lulin
    Du, Chuanjun
    Xie, Liping
    Huang, Yiran
    Wei, Qiang
    Ye, Zhangqun
    Na, Yanqun
    CHINESE JOURNAL OF CANCER RESEARCH, 2019, 31 (03) : 511 - 520
  • [47] Surgery of locally advanced prostate cancer
    Soulie, M.
    Thoulouzan, M.
    Peneau, M.
    Richaud, P.
    Ravery, V.
    PROGRES EN UROLOGIE, 2008, 18 (13): : 1031 - 1037
  • [48] Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review
    Gartrell, Benjamin A.
    Phalguni, Angaja
    Bajko, Paulina
    Mundle, Suneel D.
    Mccarthy, Sharon A.
    Brookman-May, Sabine D.
    De Solda, Francesco
    Jain, Ruhee
    Ko, Wellam Yu
    Ploussard, Guillaume
    Hadaschik, Boris
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (06): : 1216 - 1227
  • [49] Survival and secondary interventions following treatment for locally-advanced prostate cancer
    Sussman, Rachael
    Carvalho, Filipe L. F.
    Harbin, Andrew
    Zheng, Choayi
    Lynch, John H.
    Stamatakis, Lambros
    Hwang, Jonathan
    Williams, Stephen B.
    Hu, Jim C.
    Kowalczyk, Keith J.
    CANADIAN JOURNAL OF UROLOGY, 2018, 25 (05) : 9516 - 9524
  • [50] ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer
    McLaughlin, Patrick W.
    Liss, Adam L.
    Nguyen, Paul L.
    Assimas, Dean G.
    D'Amico, Anthony V.
    Gottschalk, Alexander R.
    Gustafson, Gary S.
    Keol, Sameer R.
    Liauw, Stanley L.
    Lloyd, Shane
    Movsas, Benjamin
    Prestidg, Bradley R.
    Showalter, Timothy N.
    Taira, Al V.
    Vapiwal, Neha
    Davi, Brian J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (01): : 1 - 10